Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2025)

Avalo Therapeutics' Deferred Taxes history spans 9 years, with the latest figure at $131000.0 for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 14.91% year-over-year to $131000.0; the TTM value through Dec 2025 reached $165000.0, up 44.74%, while the annual FY2025 figure was $165000.0, 44.74% up from the prior year.
  • Deferred Taxes reached $131000.0 in Q4 2025 per AVTX's latest filing, up from $10000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $131000.0 in Q4 2025 to a low of -$62000.0 in Q4 2021.
  • Average Deferred Taxes over 5 years is $14950.0, with a median of $8000.0 recorded in 2022.
  • The largest YoY upside for Deferred Taxes was 1366.67% in 2024 against a maximum downside of 275.0% in 2024.
  • A 5-year view of Deferred Taxes shows it stood at -$62000.0 in 2021, then skyrocketed by 112.9% to $8000.0 in 2022, then plummeted by 212.5% to -$9000.0 in 2023, then surged by 1366.67% to $114000.0 in 2024, then increased by 14.91% to $131000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Deferred Taxes are $131000.0 (Q4 2025), $10000.0 (Q3 2025), and $16000.0 (Q2 2025).